Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Valeant Will Add Salix To Roster
by Lisa M. Jarvis
March 2, 2015
| A version of this story appeared in
Volume 93, Issue 9
Specialty pharmaceuticals firm Valeant will pay $14.5 billion, including debt, to acquire Raleigh, N.C.-based Salix Pharmaceuticals. The deal, the largest in a series of purchases for Valeant, adds a portfolio of gastrointestinal treatments and an experienced sales team. Valeant expects to carve $500 million in annual costs out of the combined company by cutting R&D and corporate overhead. Salix’s specialty sales force and hospital reimbursement teams will be spared. Valeant operates with a minuscule R&D budget, focusing instead on growth through acquisition.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter